Tessellate BIO Appoints Lara Boyd as Chief Business Officer Amid Rapid Growth
Portfolio - People | Nov 04, 2024 | Biogeneration Ventures (BGV)
Tessellate BIO, a preclinical stage biotechnology firm, has announced the appointment of Dr. Lara Boyd as the Chief Business Officer. Tessellate BIO is focused on discovering and developing precision oncology therapies with an emphasis on Synthetic Lethality approaches. This appointment comes in the context of Tessellate BIO's rapid growth in the field of cancer treatment development. Dr. Boyd brings extensive expertise from her previous role at F-star Therapeutics, where she was involved in business development and corporate strategy. Tessellate BIO is backed by life science investors such as BioGeneration Ventures and Forbion, underpinning its strategy of pioneering small molecule drug discovery for oncology targets. The firm leverages research from globally recognized institutions to build a pipeline of innovative treatments. The company's operations are based in the Netherlands with research labs at the Stevenage Bioscience Catalyst in the UK.
Sectors
- Biotechnology
- Pharmaceuticals
- Investment
Geography
- Netherlands – Tessellate BIO is headquartered in the Netherlands, indicating significant geographical relevance for its corporate and strategic activities.
- United Kingdom – The company's research labs are located in Stevenage, UK, engaging local biotech ecosystems and research collaborations.
Industry
- Biotechnology – The article is centered around Tessellate BIO, a company heavily involved in biotechnology, focusing on precision oncology and the discovery of new cancer treatments through advancements in Synthetic Lethality.
- Pharmaceuticals – Tessellate BIO's work in drug development and oncology therapeutics is directly related to the pharmaceuticals industry, exploring innovative treatments for cancer.
- Investment – The involvement of BioGeneration Ventures and Forbion as investors highlights the significance of investment in life sciences and biotechnology sectors.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Tessellate BIO | Target Company | Company | A preclinical stage biotechnology company focusing on precision oncology drugs using Synthetic Lethality. |
| Lara Boyd | Chief Business Officer | Person | Newly appointed Chief Business Officer at Tessellate BIO, with previous roles in business development at F-star Therapeutics and Cancer Research UK. |
| BioGeneration Ventures (BGV) | Investor | Company | A life science investment firm that supports Tessellate BIO. |
| Andree Blaukat | CEO | Person | The CEO of Tessellate BIO who remarked on the significance of Lara Boyd’s appointment. |
| Forbion | Investor | Company | A life science investment firm providing financial backing to Tessellate BIO. |
| Charles Consultants | Public Relations | Company | The media contact for inquiries about Tessellate BIO, providing PR services. |